The meta-analysis showed that SGLT2 inhibitors significantly reduced the ALT levels in patients with NAFLD compared with other drugs (WMD -5.36 [95% CI: -8.86, -1.85], p = 0.003). Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.